Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Hormone Therapy Response Associated with Signaling Activity in Circulating Cancer Cells

By BiotechDaily International staff writers
Posted on 07 Nov 2012
A study monitoring hormone receptor activity in tumor cells from patients being treated for resistant metastatic prostate cancer has found that such monitoring may be useful for indicating which patients will be more likely to respond well to continued therapy.

Treatments that inhibit the androgen receptor (AR) pathway, androgen-deprivation therapy (ADT), are initially highly effective in most patients with metastatic prostate cancer (MPC); however, since cancer cells often develop resistance, secondary hormonal therapies are being tested to suppress androgen receptor reactivation. There are variable responses to such secondary therapy, but no reliable biomarkers are available to guide the use of AR pathway inhibitors in treating resistant MPC. A collaborative team of researchers led by Prof. Daniel A. Haber, MD, PhD, and director of the Massachusetts General Hospital Cancer Center (Charlestown, MA, USA) have now established a method using microfluidic capture of circulating tumor cells (CTCs) to isolate cancer cells from the blood of patients with MPC and single-cell immunofluorescence analysis to measure androgen receptor signaling activity in the individual CTCs.

Monitoring was performed on CTCs from patients with castration-resistant prostate cancer (CRPC), before and after therapeutic interventions. Prior to the initiation of ADT, the AR pathway was turned on in most CTCs from newly diagnosed patients. Initiation of first-line ADT induced a profound switch from “AR-on” to “AR-off” CTCs. In patients whose cancer had become resistant after initially responding well to androgen-deprivation therapy, the CTCs population became highly variable - some CTCs were AR-on, others AR-off, and still others had characteristics of both AR-on and AR-off. The presence of cells with a mixed AR signaling pattern was associated with an adverse treatment outcome. In addition, in patients treated with a new drug, abiraterone acetate, which achieves more complete androgen deprivation than earlier treatments, an increased percentage of AR-on CTCs despite abiraterone treatment was associated with decreased overall survival.

The assay may provide a valuable marker to help target such treatments to patients more likely to respond to second-line therapies. "This study is a proof of principle that it is possible to monitor, in patients with metastatic prostate cancer, the androgen receptor signaling pathway in real time, repeatedly and noninvasively," said Prof. Haber. He added, "As more drugs are developed that target the different pathways that drive the recurrence of metastatic prostate cancer in different patients, it will become essential to know which drug and which pathway is relevant in each patient. Our assay will be an effective way to interrogate the tumor and follow it during the course of treatment to monitor therapy response and the emergence of drug resistance."

The study was published early online October 23, 2012, in Cancer Discovery, a journal of the American Association for Cancer Research.

Related Links:
Massachusetts General Hospital Cancer Center
American Association for Cancer Research


SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A 3-dimensional picture reveals how the antibodies in the experimental drug Zmapp bind to Ebola virus (Photo courtesy of the Scripps Research Institute).

Electron Microscope Imaging Shows How Experimental Anti-Ebola Drug Works

Electron microscope imaging has revealed how the experimental drug ZMapp binds to the Ebolavirus and provides insights into how the drug prevents growth of the pathogen. ZMapp, which was developed by... Read more

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.